Xarelto, part of a new generation of anticoagulants, is a prescription medication used to reduce the risk of stroke and blood clots. It is currently at the center of a new lawsuit filed by the wife of a man who died because of uncontrollable bleeding. This is just the latest of a rapidly growing number of Xarelto bleeding lawsuits that are currently being filed through the country.
What is Xarelto, and what is the problem?
Xarelto, introduced in 2011, is a joint venture between Bayer and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary. Kind of like Big 3 of the Miami Heat coming together. But in this case, the goal was not championships but to make gobs and gobs of money. Intended to replace warfarin (Coumadin), Xarelto has been promoted as superior to warfarin, and others like it, because it is easier to take and requires less frequent monitoring to maintain the correct dose. The downfall? First, it causes excessive bleeding. Second, there is no good reversal agent or antidote to stop bleeding should an event occur. While Bayer and Johnson & Johnson have indicated that they are working with a company to develop a reversal agent for Xarelto, there is not one currently available, making the drug unreasonably dangerous and defective.